Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 24, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 26, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-26-012473
Filed / recorded
Feb 26, 2026, 10:55 PM UTC
Added to OQRO
Oct 6, 2026, 10:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BIOLIFE SOLUTIONS INC
Issuer CIK
834365
Ticker
BLFS
Reporting person
Aby J. Mathew
Relationship
Officer
Officer title
EVP & Chief Scientific Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 24, 2026
Transaction code
A
Shares / units
20,096
Acquired / disposed
Acquired (A)
Shares owned after
369,446
Ownership form
Direct
Amendment
No
Footnotes from the filing
The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.